Al Hammadi Company for Development and Investment Co. reported a net profit of SAR 77.2 million for the first nine months of 2017, a 23.6 percent year-on-year (YoY) increase, attributed to a 23 percent leap in net revenue on an increase in the number of patients and inpatient nights. The healthcare firm also cited the optimization of contractual terms with some customers.
| Item | 9m 2016 | 9m 2017 | Change |
|---|---|---|---|
| Revenues | 423.59 | 519.94 | 22.7 % |
| Gross Income | 168.78 | 174.08 | 3.1 % |
| Operating Income | 80.23 | 92.95 | 15.9 % |
| Net Income | 62.47 | 77.21 | 23.6 % |
| Average Shares | 160.00 | 160.00 | - |
| EPS (Riyals) | 0.39 | 0.48 | 23.6 % |
Q3 net profit rose 13.8 percent YoY to SAR 23.6 million due to a higher net revenue from an increase in inpatient nights.
Compared to the previous quarter, Q3 net earnings fell 8.1 percent due to lower revenues, as a result of the seasonal impact of summer vacations.
| Item | Q3 2016 | Q3 2017 | Change |
|---|---|---|---|
| Revenues | 141.35 | 163.01 | 15.3 % |
| Gross Income | 56.48 | 53.91 | (4.5 %) |
| Operating Income | 25.97 | 26.46 | 1.9 % |
| Net Income | 20.73 | 23.59 | 13.8 % |
| Average Shares | 160.00 | 160.00 | - |
| EPS (Riyals) | 0.13 | 0.15 | 13.8 % |
| Period | Revenues | Change | Gross Income | Change | Net Income | Change | EPS(Riyal) |
|---|---|---|---|---|---|---|---|
| Q1 2017 | 180.23 | 25.0 % | 62.02 | 13.3 % | 27.97 | 32.3 % | 0.17 |
| Q2 2017 | 176.71 | 28.0 % | 58.16 | 1.0 % | 25.66 | 24.4 % | 0.16 |
| Q3 2017 | 163.01 | 15.3 % | 53.91 | (4.5 %) | 23.59 | 13.8 % | 0.15 |
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2017 | 38.83 % | 24.74 % | 12.43 % |
| Q2 2017 | 36.71 % | 24.09 % | 12.46 % |
| Q3 2017 | 35.22 % | 23.41 % | 12.48 % |
| Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2017 | 160.00 | 0.50 | 0.50 | 8.75 |
| Q2 2017 | 160.00 | 0.53 | 0.53 | 8.89 |
| Q3 2017 | 160.00 | 0.55 | 0.55 | 9.04 |
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| Q1 2017 | 61.37 | 61.37 | 3.50 |
| Q2 2017 | 58.51 | 58.51 | 3.49 |
| Q3 2017 | 47.94 | 47.94 | 2.91 |
Q3 2017
| Period | healthy services and other | Pharmaceutical sales revenue - Pharmacies |
|---|---|---|
| Q1 2017 | 150.74 | 29.49 |
| Q2 2017 | 147.45 | 29.26 |
| Q3 2017 | 136.70 | 26.31 |
| Item | Q3 2017 (e) | Q3 2017 (a) | Change |
|---|---|---|---|
| Average | 27.56 | 23.59 | (14.4 %) |
| Item | Q3 2017 (e) | Q3 2017 (a) | Change |
|---|---|---|---|
| OSOOL AND BAKHEET | 26.10 | 23.59 | (9.6) % |
| Al Rajhi Capital | 27.00 | 23.59 | (12.6) % |
| Arbah Capital | 27.00 | 23.59 | (12.6) % |
| AlJazira Capital | 27.50 | 23.59 | (14.2) % |
| Albilad Capital | 28.00 | 23.59 | (15.8) % |
| Sico | 28.00 | 23.59 | (15.8) % |
| SNB Capital | 28.10 | 23.59 | (16.1) % |
| Alistithmar Capital | 28.81 | 23.59 | (18.1) % |
| Current | |
| Market Cap (M Riyal) | 7,512.00 |
| Enterprise Value (EV) (M) | 7,510.11 |
| Shares Outstanding ((M)) | 160.00 |
| EPS ( Riyal) (TTM) | 1.79 |
| Book Value (BV) ( Riyal) | 11.58 |
| Par Value ( Riyal) | 10.00 |
| Adjusted P/E (Last12) | 26.88 |
| P/E (TTM) | 26.27 |
| Price/book | 4.05 |
| Return on Average Assets (%) (TTM) | 11.1 |
| Return on Average Equity (%) (TTM) | 15.9 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}